A side-by-side comparison of two Healthcare investors: Shenzhen Capital Group (Power Score 80/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Shenzhen Capital Group | Vivo Capital | |
|---|---|---|
| Power Score™ | 80/100 | 83/100 |
| Assets Managed | US$50B+ (approx.; the firm's figure is RMB 360.273bn of paid-in capital across all funds it and its subsidiaries manage at 31 December 2024, per its 2025 bond credit rating report - paid-in fund scale, not net asset value) | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 1999 | 1996 |
| Headquarters | Shenzhen, China | Palo Alto, CA |
| Sectors | Semiconductors, Technology, Robotics, Industrial Manufacturing, Advanced Manufacturing, Clean Energy, Biotech, Pharmaceuticals, Infrastructure Software | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
Shenzhen Capital Group describes itself on its own site as a state-owned comprehensive investment group whose core business is venture capital, and says its business spans venture capital, real estate investment, public mutual funds and asset securitisation. Within venture capital it says it manages venture funds, funds of funds, S funds and buyout funds, and it has managed government guidance funds since setting up China's first government guidance sub-fund with the Suzhou municipal government in 2007 and taking on entrusted management of the Shenzhen municipal guidance fund from 2016. Chairman Zuo Ding stated in a 25 February 2026 article on the group's site that more than 85 per cent of the 1,800 plus companies the group has directly invested in are start-up stage or growth stage, that more than 90 per cent are hard technology companies, and that the focus areas cover semiconductors, robotics, new materials, biopharmaceuticals and industrial software. The group's investment departments are organised by both sector (information technology, high-end equipment, general equipment, new materials, new energy, biopharmaceuticals) and region (Greater Bay Area, North China, Northeast, Central China, Southeast, Jiangsu, Shanghai, West China). Its wholly owned subsidiary Red Soil Innovation Fund Management, set up in June 2014, was the first public mutual fund management company in China established by a private equity institution.
View full Shenzhen Capital Group profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →